About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Lep
leptin
MGI:104663
241 phenotypes from 11 alleles in 27 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Lepm1Btlr/Lepm1Btlr
C57BL/6J-Lepm1Btlr 		increased body fat mass J:189953
obese J:189953
Lepm1Yst/Lepm1Yst
C57BL/6J-Lepm1Yst 		abnormal eating behavior J:167736
abnormal gonadal fat pad morphology J:167736
decreased body temperature J:167736
hepatic steatosis J:167736
impaired glucose tolerance J:167736
increased body length J:167736
increased body weight J:167736
increased brown adipose tissue amount J:167736
increased brown fat cell lipid droplet size J:167736
increased circulating cholesterol level J:167736
increased circulating glucose level J:167736
increased circulating insulin level J:167736
increased circulating leptin level J:167736
increased circulating triglyceride level J:167736
increased defecation amount J:167736
increased heart weight J:167736
increased inguinal fat pad weight J:167736
increased kidney weight J:167736
increased liver weight J:167736
increased macrophage cell number J:167736
increased total body fat amount J:167736
increased white adipose tissue amount J:167736
increased white fat cell number J:167736
increased white fat cell size J:167736
infertility J:167736
insulin resistance J:167736
obese J:167736
pale liver J:167736
polyuria J:167736
Lepm2Btlr/Lepm2Btlr
C57BL/6J-Lepm2Btlr 		obese J:234238
Lepob/Lep+
involves: 129X1/SvJ * C57BL/6 		increased liver weight J:76479
Lepob/Lep+
involves: C57BL/6J 		increased bone mass J:60001
Lepob/Lepob-2J
involves: C57BL/6J * SM/Ckc 		obese J:30778
Lepob/Lepob
B6.Cg-Lepob/J 		abnormal body weight J:22025, J:29075
abnormal bone marrow morphology J:189019
abnormal circulating cholesterol level J:18161
abnormal circulating glucose level J:5400
abnormal epididymal fat pad morphology J:22377
abnormal food intake J:122746
abnormal frequency of paradoxical sleep J:115771
abnormal liver weight J:22377
abnormal muscle morphology J:151518
abnormal myocardial fiber morphology J:103063, J:104171, J:111488
abnormal myocardial fiber physiology J:104171
abnormal oxygen consumption J:22025, J:22377
abnormal pain threshold J:152019
abnormal pancreatic beta cell physiology J:5400
abnormal protein level J:22025
abnormal skeletal muscle fiber type ratio J:151518
abnormal sleep pattern J:115771
abnormal sympathetic nervous system physiology J:145998
abnormal urine catecholamine level J:4033
abnormal urine homeostasis J:4033
allodynia J:152019
decreased body temperature J:129662
decreased cardiac muscle contractility J:104171, J:111488
decreased circulating glucose level J:129554, J:145998, J:189019
decreased food intake J:29075
decreased insulin secretion J:145998
decreased locomotor activity J:115771, J:122746
decreased NK cell number J:117826
decreased oxygen consumption J:22377
decreased physiological sensitivity to xenobiotic J:344866
decreased skeletal muscle fiber size J:151518
decreased skeletal muscle mass J:151518
decreased white fat cell number J:22377
enlarged pancreatic islets J:5400
female infertility J:122746
fragmentation of sleep/wake states J:115771
heart left ventricle hypertrophy J:103063
hyperalgesia J:152019
hyperglycemia J:5400, J:65486, J:122746
hypoglycemia J:5400
impaired glucose tolerance J:104171, J:107486
increased body weight J:185261
increased circulating cholesterol level J:18161
increased circulating HDL cholesterol level J:18161
increased circulating insulin level J:5400, J:104171, J:122746
increased circulating LDL cholesterol level J:18161
increased circulating triglyceride level J:18161, J:104171
increased circulating VLDL cholesterol level J:18161
increased fat cell size J:189019
increased food intake J:129662
increased growth rate J:5400
increased insulin secretion J:145998
increased interscapular fat pad weight J:22377
increased metastatic potential J:117826
increased myocardial fiber size J:104171
increased oxygen consumption J:22377
increased percent body fat/body weight J:122746
insulin resistance J:104171
lung inflammation J:115772
obese J:103063, J:104171
polyphagia J:122746
Lepob/Lepob
B6.Cg-Lepob/JBomTac 		increased circulating triglyceride level J:149091
Lepob/Lepob
B6.Cg-Lepob/JRj 		abnormal cell cycle J:220381
abnormal hepatocyte physiology J:220381
hepatic steatosis J:277927
normal homeostasis/metabolism phenotype J:277927
increased body weight J:277927
increased cholesterol level J:277927
increased circulating free fatty acids level J:277927
increased hepatocyte apoptosis J:277927
increased susceptibility to diet-induced obesity J:277927
liver fibrosis J:277927
liver inflammation J:277927
macrovesicular hepatic steatosis J:277927
oxidative stress J:220381
Lepob/Lepob
B6.Cg-Lepob/OlaHsd 		abnormal acute inflammation J:124815
abnormal chemokine secretion J:124815
abnormal digestive system physiology J:124815
abnormal intestinal epithelium morphology J:124815
increased interleukin-6 secretion J:124815
increased susceptibility to endotoxin shock J:124815
liver inflammation J:124815
Lepob/Lepob
BKS.Cg-Lepob/J 		abnormal circulating cholesterol level J:18161
abnormal circulating glucose level J:5400
abnormal pancreatic beta cell physiology J:5400
hyperglycemia J:5400
increased circulating cholesterol level J:18161
increased circulating HDL cholesterol level J:18161
increased circulating insulin level J:5400
increased circulating LDL cholesterol level J:18161
increased circulating triglyceride level J:18161
increased circulating VLDL cholesterol level J:18161
increased growth rate J:5400
increased urine glucose level J:5400
polyuria J:5400
premature death J:5400
small pancreatic islets J:5400
Lepob/Lepob
BTBR.Cg-Lepob 		hyperglycemia J:65486
Lepob/Lepob
BTBR.Cg-Lepob/WiscJ 		abnormal pancreatic islet morphology J:106121
abnormal podocyte morphology J:185261
albuminuria J:185261
normal cardiovascular system phenotype J:185261
decreased pancreatic beta cell mass J:106121
enlarged kidney J:185261
expanded mesangial matrix J:185261
glomerulosclerosis J:185261
hyperglycemia J:106121, J:185261
hypotension J:185261
impaired glucose tolerance J:106121
increased blood urea nitrogen level J:185261
increased body weight J:185261
increased cholesterol level J:185261
increased circulating insulin level J:106121
increased circulating triglyceride level J:106121, J:185261
increased kidney weight J:185261
increased renal glomerulus basement membrane thickness J:185261
insulin resistance J:106121
mesangiolysis J:185261
renal glomerulus hypertrophy J:185261
renal interstitial fibrosis J:185261
small pancreatic islets J:106121
Lepob/Lepob
D2.Cg-Lepob/Chua 		abnormal pancreatic islet morphology J:78850
decreased pancreatic beta cell number J:78850
hyperglycemia J:78850
increased circulating insulin level J:78850
increased pancreatic beta cell number J:78850
obese J:78850
Lepob/Lepob
FVB.Cg-Lepob/Chua 		hyperglycemia J:78850
increased circulating insulin level J:78850
Lepob/Lepob
involves: 129 * C57BL/6 		abnormal lipid level J:121534
abnormal pancreatic islet morphology J:121534
decreased locomotor activity J:121534
enlarged pancreatic islets J:121534
hepatic steatosis J:121534
increased body weight J:121534
increased circulating insulin level J:121534
increased insulin secretion J:121534
increased pancreatic islet number J:121534
increased percent body fat/body weight J:121534
insulin resistance J:121534
polyphagia J:121534
Lepob/Lepob
involves: 129X1/SvJ * C57BL/6 		abnormal adipose tissue amount J:107169
abnormal branching of the mammary ductal tree J:76479
abnormal circulating hormone level J:76479
abnormal intestine morphology J:107169
abnormal vagina orifice morphology J:76479
absent corpus luteum J:76479
decreased circulating pancreatic peptide level J:76479
decreased circulating testosterone level J:76479, J:107169
decreased lean body mass J:107169
decreased primary ovarian follicle number J:76479
decreased secondary ovarian follicle number J:76479
decreased seminal vesicle weight J:76479
decreased testis weight J:76479, J:107169
female infertility J:76479
hyperglycemia J:107169
increased body weight J:107169
increased circulating cholesterol level J:107169
increased circulating corticosterone level J:76479, J:107169
increased circulating insulin level J:76479, J:107169
increased circulating leptin level J:76479
increased circulating triglyceride level J:107169
increased kidney weight J:107169
increased liver weight J:107169
increased pancreas weight J:107169
male infertility J:76479, J:107169
polyphagia J:107169
prolonged diestrus J:76479
prolonged estrous cycle J:76479
prolonged estrus J:76479
Lepob/Lepob
involves: BTBR * C57BL/6 * V stock 		decreased pancreatic beta cell number J:65486
disorganized pancreatic islets J:65486
hyperglycemia J:65486
increased circulating insulin level J:65486
pancreatic islet hyperplasia J:65486
Lepob/Lepob
involves: C57BL/6 		decreased CD4-positive, alpha-beta T cell number J:164339
decreased splenocyte number J:164339
decreased T cell proliferation J:164339
increased circulating cholesterol level J:72027
increased circulating HDL cholesterol level J:72027
increased circulating triglyceride level J:72027
increased liver cholesterol level J:72027
increased liver triglyceride level J:72027
Lepob/Lepob
involves: C57BL/6J 		abnormal behavior J:112820
abnormal cardiovascular system physiology J:116841
abnormal colon goblet cell morphology J:109110
abnormal corticosterone level J:13151
abnormal epidermal layer morphology J:121015
abnormal glucose homeostasis J:92558
abnormal hormone level J:13151
abnormal insulin secretion J:14402, J:22634
abnormal intestinal mucosa morphology J:109110
abnormal muscle contractility J:106205
abnormal osteoclast differentiation J:60001
abnormal postnatal growth J:6236
abnormal respiratory electron transport chain J:116841
abnormal retina vasculature morphology J:92072
abnormal skeleton development J:60001
decreased locomotor activity J:219118
decreased nerve conduction velocity J:121015
enlarged pancreatic islets J:219118
hepatic steatosis J:219118
hyperglycemia J:92558, J:219118
impaired glucose tolerance J:86303, J:219118
increased adrenocorticotropin level J:13151
increased body length J:219118
increased bone mass J:60001
increased circulating corticosterone level J:60001
increased circulating insulin level J:92558
increased fasting circulating glucose level J:219118
increased fat cell size J:5765, J:219118
increased gonadal fat pad weight J:219118
increased heart weight J:116841
increased inguinal fat pad weight J:219118
increased interscapular fat pad weight J:219118
increased lean body mass J:219118
increased liver weight J:219118
increased percent body fat/body weight J:219118
increased thermal nociceptive threshold J:121015
insulin resistance J:219118
obese J:92558, J:219118
osteopetrosis J:60001
polyphagia J:219118
postnatal lethality, incomplete penetrance J:219118
Lepob/Lepob
involves: STOCK Mlphln a Tgfawa1 Cdh23v Ednrbs 		abnormal arteriole morphology J:151096
abnormal cortical plate morphology J:105139
abnormal embryonic neuroepithelium morphology J:105139
abnormal fat cell morphology J:5253, J:7702
abnormal gland physiology J:7702
abnormal glucose homeostasis J:7702
abnormal hormone level J:7702
abnormal long bone epiphyseal plate morphology J:102535
abnormal long bone epiphyseal plate proliferative zone J:102535
abnormal long bone hypertrophic chondrocyte zone J:102535
abnormal microglial cell physiology J:115569
abnormal nucleotide metabolism J:260830
abnormal pancreatic beta cell morphology J:7702
abnormal response to cardiac infarction J:219470
abnormal vascular wound healing J:135034
abnormal white adipose tissue morphology J:260830
decreased activity of thyroid gland J:7702
decreased body length J:13066
decreased body temperature J:12010
decreased bone mass J:7702
decreased circulating tumor necrosis factor level J:115569
decreased embryonic neuroepithelial cell proliferation J:105139
decreased embryonic neuroepithelium thickness J:105139
decreased length of long bones J:102535
decreased liver triglyceride level J:199803
decreased susceptibility to hepatic steatosis J:199803
female infertility J:7702
hyperglycemia J:7702
hypersecretion of corticosterone J:7702
impaired adaptive thermogenesis J:7702, J:12010
impaired glucose tolerance J:7702
increased adrenocorticotropin level J:7702
increased body weight J:159285
increased circulating insulin level J:7702
increased fat cell size J:7702
increased growth rate J:13066
increased liver triglyceride level J:199803
increased pancreatic beta cell mass J:7702
increased pancreatic beta cell number J:7702
infertility J:7702
male infertility J:7702
polyphagia J:7702
reduced male fertility J:7702
short femur J:102535
short humerus J:102535
Lepob/Lepob
Tg(Npy-MAPT/Sapphire)1Rck/0
involves: C57BL/6 * CBA 		abnormal excitatory postsynaptic currents J:90242
abnormal neuron morphology J:90242
decreased body weight J:90242
decreased food intake J:90242
increased food intake J:90242
normal nervous system phenotype J:90242
Lepob/Lepob
Tg(Pomc-MAPT/Topaz)1Rck/0
involves: C57BL/6 * CBA 		abnormal inhibitory postsynaptic currents J:90242
abnormal neuron morphology J:90242
decreased body weight J:90242
decreased food intake J:90242
increased food intake J:90242
Leptm1.1Gvcao/Leptm1.1Gvcao
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJaeSor * C57BL/6J * FVB/NTac 		decreased circulating follicle stimulating hormone level J:218720
decreased circulating growth hormone level J:218720
decreased circulating leptin level J:218720
decreased circulating luteinizing hormone level J:218720
decreased circulating prolactin level J:218720
normal endocrine/exocrine gland phenotype J:218720
female infertility J:218720
increased pituitary hormone level J:218720
infertility J:218720
male infertility J:218720
obese J:218720
Leptm1.2Gvcao/Leptm1.2Gvcao
involves: 129S4/SvJaeSor * FVB/NJ * FVB/NTac 		decreased circulating follicle stimulating hormone level J:218720
decreased circulating leptin level J:218720
decreased circulating prolactin level J:218720
decreased pituitary hormone level J:218720
decreased somatotroph cell number J:218720
female infertility J:218720
increased body weight J:218720
infertility J:218720
male infertility J:218720
obese J:218720
Leptm1b(EUCOMM)Hmgu/Leptm1b(EUCOMM)Hmgu
C57BL/6N-Leptm1b(EUCOMM)Hmgu/Bay 		abnormal coat appearance J:211773
abnormal eye posterior chamber depth J:211773
abnormal retina inner nuclear layer morphology J:211773
decreased exploration in new environment J:211773
decreased grip strength J:211773
decreased heart rate J:211773
decreased heart weight J:211773
decreased locomotor activity J:211773
decreased spleen weight J:211773
decreased total retina thickness J:211773
decreased vertical activity J:211773
female infertility J:211773
increased anxiety-related response J:211773
increased cardiac stroke volume J:211773
increased cornea thickness J:211773
male infertility J:211773
prolonged QRS complex duration J:211773
short tibia J:211773
Leptm1Kry/Leptm1Kry
Not Specified 		increased bone mass J:88655
obese J:88655
Tg(Apcs-Lep)1Yog/0
involves: C57BL/6 * DBA/2 		abnormal food intake J:57075
abnormal glucose homeostasis J:57075
abnormal lipid level J:57075
decreased body weight J:57075
decreased brown adipose tissue amount J:57075
decreased circulating insulin level J:57075
decreased circulating triglyceride level J:57075
decreased liver glycogen level J:57075
decreased liver triglyceride level J:57075
decreased liver weight J:57075
decreased white adipose tissue amount J:57075
increased insulin sensitivity J:57075
small pancreatic islets J:57075
Tg(Apcs-Lep)1Yog/?
involves: C57BL/6 * DBA/2 		retina neovascularization J:92072
Tg(Apcs-Lep)1Yog/0
involves: C57BL/6J * FVB/N 		abnormal food intake J:69591
abnormal glucose homeostasis J:69591
abnormal lipid level J:69591
decreased body weight J:69591
decreased brown adipose tissue amount J:69591
decreased circulating free fatty acids level J:69591
decreased circulating glucose level J:69591
decreased circulating insulin level J:69591
decreased circulating triglyceride level J:69591
decreased white adipose tissue amount J:69591
increased insulin sensitivity J:69591
small liver J:69591
small pancreatic islets J:69591
Tg(Apcs-Lep)1Yog/0
Not Specified 		decreased bone mass J:88655
Tg(Apoe-Lep)1Kry/0
involves: FVB 		abnormal bone ossification J:88655
abnormal food intake J:88655
decreased bone mass J:88655
decreased total body fat amount J:88655
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory